109 related articles for article (PubMed ID: 15366425)
1. Captopril suppresses post-transplantation angiogenic activity in rat allograft coronary vessels.
Crawford SE; Mavroudis C; Backer CL; Huang X; Mu Y; Volpert OV; Stellmach V; Pahl E; Huang L
J Heart Lung Transplant; 2004 Jun; 23(6):666-73. PubMed ID: 15366425
[TBL] [Abstract][Full Text] [Related]
2. Captopril and platelet-activating factor (PAF) antagonist prevent cardiac allograft vasculopathy in rats: role of endogenous PAF and PAF-like compounds.
Crawford SE; Huang L; Hsueh W; Takami H; Gonzalez-Crussi F; Backer CL; Mu Y; Liu H; Mavroudis C
J Heart Lung Transplant; 1999 May; 18(5):470-7. PubMed ID: 10363692
[TBL] [Abstract][Full Text] [Related]
3. Captopril reduces graft coronary artery disease in a rat heterotopic transplant model.
Kobayashi J; Crawford SE; Backer CL; Zales VR; Takami H; Hsueh C; Huang L; Mavroudis C
Circulation; 1993 Nov; 88(5 Pt 2):II286-90. PubMed ID: 8222167
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor-2 mediates Angiotensin-converting enzyme inhibitor-induced angiogenesis in coronary endothelium.
Donnini S; Solito R; Giachetti A; Granger HJ; Ziche M; Morbidelli L
J Pharmacol Exp Ther; 2006 Nov; 319(2):515-22. PubMed ID: 16868034
[TBL] [Abstract][Full Text] [Related]
5. Captopril and vascular endothelial growth factor in a mouse model of retinopathy.
Higgins RD; Yan Y; Geng Y; Sharma J; Barr SM
Curr Eye Res; 2003 Aug; 27(2):123-9. PubMed ID: 14632165
[TBL] [Abstract][Full Text] [Related]
6. Early captopril treatment inhibits DNA synthesis in endothelial cells and normalization of maximal coronary flow in infarcted rat hearts.
Nelissen-Vrancken HJ; Kuizinga MC; Daemen MJ; Smits JF
Cardiovasc Res; 1998 Oct; 40(1):156-64. PubMed ID: 9876328
[TBL] [Abstract][Full Text] [Related]
7. AP-1 and STAT-1 decoy oligodeoxynucleotides attenuate transplant vasculopathy in rat cardiac allografts.
Stadlbauer TH; Wagner AH; Hölschermann H; Fiedel S; Fingerhuth H; Tillmanns H; Bohle RM; Hecker M
Cardiovasc Res; 2008 Sep; 79(4):698-705. PubMed ID: 18511434
[TBL] [Abstract][Full Text] [Related]
8. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.
Volpert OV; Ward WF; Lingen MW; Chesler L; Solt DB; Johnson MD; Molteni A; Polverini PJ; Bouck NP
J Clin Invest; 1996 Aug; 98(3):671-9. PubMed ID: 8698858
[TBL] [Abstract][Full Text] [Related]
9. Effect of captopril on skeletal muscle angiogenic growth factor responses to exercise.
Gavin TP; Spector DA; Wagner H; Breen EC; Wagner PD
J Appl Physiol (1985); 2000 May; 88(5):1690-7. PubMed ID: 10797131
[TBL] [Abstract][Full Text] [Related]
10. Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model: feasibility of restoring impaired angiogenic capacity in the aging heart.
Edelberg JM; Lee SH; Kaur M; Tang L; Feirt NM; McCabe S; Bramwell O; Wong SC; Hong MK
Circulation; 2002 Feb; 105(5):608-13. PubMed ID: 11827927
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril.
Furukawa Y; Matsumori A; Hirozane T; Sasayama S
Circulation; 1996 Jan; 93(2):333-9. PubMed ID: 8548907
[TBL] [Abstract][Full Text] [Related]
12. Improvement of endocardial and vascular endothelial function on myocardial performance by captopril treatment in postinfarct rat hearts.
Qi XL; Stewart DJ; Gosselin H; Azad A; Picard P; Andries L; Sys SU; Brutsaert DL; Rouleau JL
Circulation; 1999 Sep; 100(12):1338-45. PubMed ID: 10491380
[TBL] [Abstract][Full Text] [Related]
13. Cardiomyopathy development protection after myocardial infarction in rats: Successful competition for major dihydropyridines' common metabolite against captopril.
Mitręga KA; Spałek AM; Nożyński J; Porc M; Stankiewicz M; Krzemiński TF
PLoS One; 2017; 12(6):e0179633. PubMed ID: 28636634
[TBL] [Abstract][Full Text] [Related]
14. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo.
Fabre JE; Rivard A; Magner M; Silver M; Isner JM
Circulation; 1999 Jun; 99(23):3043-9. PubMed ID: 10368123
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor receptor upregulation in response to cell-based angiogenic gene therapy.
Yau TM; Li G; Zhang Y; Weisel RD; Mickle DA; Li RK
Ann Thorac Surg; 2005 Jun; 79(6):2056-63. PubMed ID: 15919309
[TBL] [Abstract][Full Text] [Related]
16. Platelet-activating factor (PAF) induces corneal neovascularization and upregulates VEGF expression in endothelial cells.
Ma X; Ottino P; Bazan HE; Bazan NG
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):2915-21. PubMed ID: 15326102
[TBL] [Abstract][Full Text] [Related]
17. Herbimycin A inhibits angiogenic activity in endothelial cells and reduces neovascularization in a rat model of retinopathy of prematurity.
McCollum GW; Rajaratnam VS; Bullard LE; Yang R; Penn JS
Exp Eye Res; 2004 May; 78(5):987-95. PubMed ID: 15051479
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia paradoxically inhibits the angiogenic response of isolated vessel explants while inducing overexpression of vascular endothelial growth factor.
Aplin AC; Nicosia RF
Angiogenesis; 2016 Apr; 19(2):133-46. PubMed ID: 26748649
[TBL] [Abstract][Full Text] [Related]
19. Effect of telmisartan on VEGF-induced and VEGF-independent angiogenic responsiveness of coronary endothelial cells in normal and streptozotocin (STZ)-induced diabetic rats.
Chaudagar KK; Mehta AA
Clin Exp Hypertens; 2014; 36(8):557-66. PubMed ID: 24490705
[TBL] [Abstract][Full Text] [Related]
20. Role of angiogenic growth factors in transplant coronary artery disease.
Lemström KB; Nykänen AI; Tikkanen JM; Krebs R; Sihvola RK; Kallio EA; Olivier R; Koskinen PK
Ann Med; 2004; 36(3):184-93. PubMed ID: 15181974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
